November 16th, 2026Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRCOnvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.Read more
November 12th, 2026GI Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in October 2026Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.Read more
November 17th, 2026Long-Term SANO Data Reinforce Active Surveillance as an Option in Esophageal Cancer Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.Read more
November 16th, 2026Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic CancerThe European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.Read more
November 13th, 20264WARD Trial Aims to Build the Case for Mavorixafor in Primary Chronic NeutropeniaThe phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.Read more
November 8th, 2026Five Under 5: Top Oncology Videos for the Week of 11/1The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.Read more